Association between MSMB rs10993994 polymorphism and susceptibility to prostate cancer: a meta-analysis and trial sequential analysis

Background: Previous studies remained controversial results related to the relationship between microseminoprotein beta gene (MSMB) rs10993994 polymorphism and prostate cancer risk. Therefore, this meta-analysis was performed to summarize such association. Methods: We searched for relevant available literatures on rs10993994 and prostate cancer until March 1st, 2016 on the databases Pubmed, Embase and web of science. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. Subgroup analyses were conducted based on ethnicity and source of controls. Then, trial sequential analysis was performed to reduce the risk of type I error and evaluate whether the results were based on firm evidence. Results: Overall, our results indicated that significant increased risk of prostate cancer was associated with rs10993994 for dominant model OR=1.28 (95% CI: 1.21-1.36), recessive model OR=1.41 (95% CI: 1.25-1.58) and homozygote model OR=1.57 (95% CI: 1.45-1.70) and heterozygote model OR=1.19 (95% CI: 1.12-1.26). In the subgroup analysis by ethnicity, significant results were detected only in Caucasian populations (dominant model: OR=1.29, 95% CI: 1.22-1.37; recessive model: OR=1.46, 95% CI: 1.33-160; homozygote model: OR=1.62, 95% CI: 1.49-1.77; heterozygote model: OR=1.19, 95% CI: 1.12-1.27). Moreover, when stratified by source of controls, statistically significant increased risks were found among both population-based control group and hospital-based control group. In the present study, such association was confirmed by trial sequential analyses. Conclusions: This meta-analysis suggests the T allele of the MSMB rs10993994 polymorphism increases prostate cancer susceptibility, which holds potential as biomarkers for prostate cancer risk.